2015•Molecular PsychiatryOpen access
Huntington’s disease cerebrospinal fluid seeds aggregation of mutant huntingtin
Zhiqun Tan, Wei Dai, Theo G.M. van Erp, Julia Overman, Angelo Demuro, Michelle A. Digman, Asa Hatami, Ricardo Albay, Emily Mitchell Sontag, Katya T Potkin, Shuo‐Chien Ling, Fabio M. Macciardi, W.E. Bunney, Jeffrey D. Long, Jane S. Paulsen, John Matthew Ringman, Ian S. C. Parker, Charles G. Glabe, Leslie Michels Thompson, Wah Keung Chiu, Steven G. Potkin
Abstract
Huntington's disease (HD), a progressive neurodegenerative disease, is caused by an expanded CAG triplet repeat producing a mutant huntingtin protein (mHTT) with a polyglutamine-repeat expansion. Onset of symptoms in mutant huntingtin gene-carrying individuals remains unpredictable. We report that synthetic polyglutamine oligomers and cerebrospinal fluid (CSF) from BACHD transgenic rats and from human HD subjects can seed mutant huntingtin aggregation in a cell model and its cell lysate. Our studies demonstrate that seeding requires the mutant huntingtin template and may reflect an underlying prion-like protein propagation mechanism. Light and cryo-electron microscopy show that synthetic seeds nucleate and enhance mutant huntingtin aggregation. This seeding assay distinguishes HD subjects from healthy and non-HD dementia controls without overlap (blinded samples). Ultimately, this seeding property in HD patient CSF may form the basis of a molecular biomarker assay to monitor HD and evaluate therapies that target mHTT.